![\"\"](\"https:\/\/lmc.ca\/wp-content\/uploads\/2019\/06\/lmc-healthcare-01.png\")
<\/a>![\"\"](\"https:\/\/lmc.ca\/wp-content\/uploads\/2020\/02\/logo.jpg\"){kind=logo}
<\/a><\/p>\n<\/p>\n
<\/p>\n
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program <\/b><\/h3>\n
Evidence-based program uses digital technology to help Canadians reduce their risk of type 2 diabetes<\/i><\/strong><\/p>\n Burlington, ON, February 27, 2020 – <\/b>Boehringer Ingelheim (Canada) Ltd. today announced its partnership with LMC Healthcare and Diabetes Canada on the Canadian Diabetes Prevention Program (CDPP), a unique initiative which aims to lower the incidence of type 2 diabetes in Canada. The partnership represents Boehringer Ingelheim\u2019s continued commitment to cross-stakeholder collaborations that drive change and advance innovation in healthcare systems to improve patient outcomes.<\/span><\/p>\n Diabetes is rising at epidemic rates; type 2 diabetes affects more than 3 million Canadians, with an additional 20 people diagnosed with the disease every hour.1 <\/span>These numbers are just the tip of the iceberg, however, with almost 6 million Canadians \u2013 close to a fifth of the population \u2013 living with prediabetes.2 <\/span>If left untreated, more than half of the people with prediabetes will have type 2 diabetes within 8 to 10 years.3 <\/span><\/p>\n Type 2 diabetes poses significant health risks, including life-threatening complications associated with heart disease, stroke and kidney failure.4 <\/span>Despite this, there is currently no effective program for preventing type 2 diabetes on a national scale in Canada.<\/p>\n \u201cAs Canada\u2019s first national diabetes prevention program, CDPP offers a solution millions of Canadians desperately need,\u201d said Mark Angelo, President and CEO, LMC Healthcare. \u201cThrough regular interactions with a personal health coach, online education modules, group workshops and digital health tracking, the program helps participants with prediabetes, or at high risk of type 2 diabetes, develop and maintain new habits, leading to long-lasting behaviour change.\u201d<\/p>\n The program is being delivered by LMC Healthcare in collaboration with Diabetes Canada, and is funded in large part by the Public Health Agency of Canada. It is available to participants at no cost. Other partners involved in the program include INTERVENT International, Dynacare, mdBriefCase, and McMaster University.<\/p>\n \u201cBoehringer Ingelheim\u2019s collaboration with LMC Healthcare underscores our dedication to delivering innovative solutions that serve current and future healthcare needs,\u201d said Andrea Sambati, President and CEO, Boehringer Ingelheim (Canada) Ltd. \u201cThe CDPP will not only improve outcomes for those most at risk of developing type 2 diabetes, but also provide significant benefits to the healthcare system \u2013 such as reducing hospitalizations and overall healthcare costs.\u201d<\/p>\n \u201cThe number of Canadians diagnosed with type 2 diabetes continues to rise dramatically,\u201d said Russell Williams, Acting President and Senior Vice President for Mission, Diabetes Canada. \u201cEvidence-based programs such as the CDPP have the potential to improve the health of Canadians, and collaborative partnerships are critical to supporting expansion across our communities.\u201d<\/p>\n The program is scheduled to conclude in September 2022. The CDPP will publish results on the effectiveness of telephone and online-based health coaching as an intervention for preventing type 2 diabetes in the Canadian population (proven effective in the United States). The results are due to be published in December 2022.<\/p>\n The CDPP accepts referrals from health care providers, as well as self-referrals. To learn more about the program visit https:\/\/lmc.ca\/diabetes-prevention<\/span>, and to determine if you are eligible, start the screening process at https:\/\/www.myintervent.com\/canrisk<\/span>.<\/p>\n Information for healthcare providers on how to refer is available at the healthcare provider FAQ https:\/\/lmc.ca\/diabetes-prevention\/physician-faq\/<\/span>.<\/p>\n <\/p>\n About Boehringer Ingelheim (Canada) Ltd. <\/b><\/p>\n Improving the health of humans and animals is the goal of Boehringer Ingelheim, a research-driven pharmaceutical company. In doing so, the focus is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients\u2019 lives. In animal health, Boehringer Ingelheim stands for advanced prevention.<\/p>\n Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas of human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.<\/p>\n As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.<\/p>\n The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec, and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.<\/p>\n More information about Boehringer Ingelheim can be found at boehringer-ingelheim.ca <\/span>or in its annual report: annualreport.boehringer-ingelheim.com <\/span><\/p>\n About LMC Healthcare <\/b><\/p>\n LMC Healthcare (LMC) is Canada\u2019s largest multi-specialty care provider in diabetes and endocrinology. LMC offers multiple diabetes-related services under one roof, making care more accessible, proactive and patient-centric than ever before. In addition to addressing the immediate diabetes-related medical needs of patients, LMC\u2019s multidisciplinary team provides education, coaching, and preventive-care services to improve patient health outcomes and minimize the risk of diabetes-related complications. The LMC team consists of world-renowned endocrinologists; certified diabetes educators (CDE) dietitians, nurses and pharmacists; optometrists and opticians; chiropodists; health coaches; and clinical research professionals. LMC\u2019s unique care delivery model makes it easier for patients to better manage their diabetes and lead healthier lives.<\/p>\n For more information <\/b><\/p>\n Diana Robson Sara McClelland<\/p>\n Proof Inc.<\/p>\n drobson@getproof.com<\/p>\n (416) 969-2815<\/p>\n <\/p>\n Sara McClelland<\/p>\n Boehringer Ingelheim (Canada) Ltd.<\/p>\n sara.mcclelland@boehringer-ingelheim.com<\/p>\n \u00a0(905) 631-4713<\/p>\n <\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":" Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program Evidence-based program uses digital technology to help Canadians reduce their risk of type 2 diabetes Burlington, ON, February 27, 2020 – Boehringer Ingelheim (Canada) Ltd. today announced its partnership with LMC Healthcare and Diabetes Canada on the Canadian Diabetes Prevention […]<\/p>","protected":false},"author":25,"featured_media":63449,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":" Evidence-based program uses digital technology to help Canadians reduce their risk of type 2 diabetes <\/i><\/strong><\/p>\r\n Burlington, ON, February 27, 2020 - <\/b>Boehringer Ingelheim (Canada) Ltd. today announced its partnership with LMC Healthcare and Diabetes Canada on the Canadian Diabetes Prevention Program (CDPP), a unique initiative which aims to lower the incidence of type 2 diabetes in Canada. The partnership represents Boehringer Ingelheim\u2019s continued commitment to cross-stakeholder collaborations that drive change and advance innovation in healthcare systems to improve patient outcomes.<\/p>\r\n Diabetes is rising at epidemic rates; type 2 diabetes affects more than 3 million Canadians, with an additional 20 people diagnosed with the disease every hour.1 <\/span>These numbers are just the tip of the iceberg, however, with almost 6 million Canadians \u2013 close to a fifth of the population \u2013 living with prediabetes.2 <\/span>If left untreated, more than half of the people with prediabetes will have type 2 diabetes within 8 to 10 years.3 <\/span><\/p>\r\n Type 2 diabetes poses significant health risks, including life-threatening complications associated with heart disease, stroke and kidney failure.4 <\/span>Despite this, there is currently no effective program for preventing type 2 diabetes on a national scale in Canada.<\/p>\r\n \u201cAs Canada\u2019s first national diabetes prevention program, CDPP offers a solution millions of Canadians desperately need,\u201d said Mark Angelo, President and CEO, LMC Healthcare. \u201cThrough regular interactions with a personal health coach, online education modules, group workshops and digital health tracking, the program helps participants with prediabetes, or at high risk of type 2 diabetes, develop and maintain new habits, leading to long-lasting behaviour change.\u201d<\/p>\r\n The program is being delivered by LMC Healthcare in collaboration with Diabetes Canada, and is funded in large part by the Public Health Agency of Canada. It is available to participants at no cost. Other partners involved in the program include INTERVENT International, Dynacare, mdBriefCase, and McMaster University.<\/p>\r\n \u201cBoehringer Ingelheim\u2019s collaboration with LMC Healthcare underscores our dedication to delivering innovative solutions that serve current and future healthcare needs,\u201d said Andrea Sambati, President and CEO, Boehringer Ingelheim (Canada) Ltd. \u201cThe CDPP will not only improve outcomes for those most at risk of developing type 2 diabetes, but also provide significant benefits to the healthcare system \u2013 such as reducing hospitalizations and overall healthcare costs.\u201d<\/p>\r\n \u201cThe number of Canadians diagnosed with type 2 diabetes continues to rise dramatically,\u201d said Russell Williams, Acting President and Senior Vice President for Mission, Diabetes Canada. \u201cEvidence-based programs such as the CDPP have the potential to improve the health of Canadians, and collaborative partnerships are critical to supporting expansion across our communities.\u201d<\/p>\r\n The program is scheduled to conclude in September 2022. The CDPP will publish results on the effectiveness of telephone and online-based health coaching as an intervention for preventing type 2 diabetes in the Canadian population (proven effective in the United States). The results are due to be published in December 2022.<\/p>\r\n The CDPP accepts referrals from health care providers, as well as self-referrals. To learn more about the program visit https:\/\/lmc.ca\/diabetes-prevention<\/span>, and to determine if you are eligible, start the screening process at https:\/\/www.myintervent.com\/canrisk<\/span>.<\/p>\r\n Information for healthcare providers on how to refer is available at the healthcare provider FAQ https:\/\/lmc.ca\/diabetes-prevention\/physician-faq\/<\/span>.<\/p>\r\n\u00a0\r\n About Boehringer Ingelheim (Canada) Ltd. <\/b><\/p>\r\n Improving the health of humans and animals is the goal of Boehringer Ingelheim, a research-driven pharmaceutical company. In doing so, the focus is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients\u2019 lives. In animal health, Boehringer Ingelheim stands for advanced prevention.<\/p>\r\n Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas of human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.<\/p>\r\n As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.<\/p>\r\n The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec, and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.<\/p>\r\n More information about Boehringer Ingelheim can be found at boehringer-ingelheim.ca <\/span>or in its annual report: annualreport.boehringer-ingelheim.com <\/span><\/p>\r\n About LMC Healthcare <\/b><\/p>\r\n LMC Healthcare (LMC) is Canada\u2019s largest multi-specialty care provider in diabetes and endocrinology. LMC offers multiple diabetes-related services under one roof, making care more accessible, proactive and patient-centric than ever before. In addition to addressing the immediate diabetes-related medical needs of patients, LMC\u2019s multidisciplinary team provides education, coaching, and preventive-care services to improve patient health outcomes and minimize the risk of diabetes-related complications. The LMC team consists of world-renowned endocrinologists; certified diabetes educators (CDE) dietitians, nurses and pharmacists; optometrists and opticians; chiropodists; health coaches; and clinical research professionals. LMC\u2019s unique care delivery model makes it easier for patients to better manage their diabetes and lead healthier lives.<\/p>\r\n For more information <\/b><\/p>\r\n Diana Robson Sara McClelland<\/p>\r\n Proof Inc.<\/p>\r\ndrobson@getproof.com\r\n\r\n(416) 969-2815\r\n\r\n\u00a0\r\n Sara McClelland<\/p>\r\nBoehringer Ingelheim (Canada) Ltd.\r\n sara.mcclelland@boehringer-ingelheim.com<\/p>\r\n \u00a0(905) 631-4713<\/p>\r\n\u00a0\r\n\n
<\/a><\/a>\r\n\r\n\u00a0\r\n\r\n\u00a0\r\nBoehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program <\/b><\/h3>\r\n
\r\n \t